Bioxodes’ Post

Evaluation of intracranial atherosclerotic stenosis burden, the use of dual antiplatelet therapy, and stroke recurrence in patients with minor stroke 🔍 Key Findings (N=3,061 minor stroke patients): • DAPT reduced 90-day stroke recurrence by 7.3% (HR 0.58, 95% CI 0.39–0.87) only in high ICAS burden patients • No significant benefit of DAPT in low ICAS burden patients • 1-year outcomes showed similar trends (3.9% absolute risk reduction) ⚠️ Clinical Takeaway: ICAS burden assessment may help stratify DAPT candidates, optimizing therapy for high-risk minor stroke patients. 🔗 Full study available here: https://lnkd.in/gmzNkZ6f 📝 Authored by: Tingting Liu, Yongle Wang, Kaili Zhang, Haimei Fan, Xinyi Li, Xuemei Wu, Xiaoyuan Niu

The EVOKE Study is the first double-blinded, pivotal randomized clinical trial to show the longest-lasting patient outcomes ever reported in spinal cord stimulation. It's the most rigorous study in SCS history! 36-Month Highlights: ➡️ 83% of patients had ≥50% VAS reduction ➡️ 59% of patients had ≥80% VAS reduction ➡️ ZERO Explants Due to Loss of Efficacy ➡️ 89% of Patients Chose Closed-Loop Therapy These results represent lives changed and confidence restored in the Evoke® System—a therapy built to last. Source: Mekhail NA, et al. Reg Anesth Pain Med. 2024;49(5):346-354. #EvokeSystem #ClosedLoopTherapy #ChronicPain #Durability #ClinicalExcellence #SaludaMedical Risks and Important Safety Info https://lnkd.in/d2XZ_Asn   Individual results may vary. Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs. Evoke® System with EVA™ is available in select geographies.

Saluda Medical #SCS #double-blinded, pivotal randomized clinical trial 36-Month Highlights: ➡️ 83% of patients had ≥50% VAS reduction ➡️ 59% of patients had ≥80% VAS reduction ➡️ ZERO Explants Due to Loss of Efficacy ➡️ 89% of Patients Chose Closed-Loop Therapy

Dual therapies, differential effects? ↖️↘️ Dual antiplatelet therapy (DAPT) or dual antithrombotic therapy (DAT): Is it a distinction without a difference for patients with chronic coronary syndrome (CCS)? Haddad et al. (2025) note that DAPT (with ticagrelor) results in longer bleeding times, while DAT (with rivaroxaban) shortens clot lysis time. Notably, both regimens demonstrated similar antithrombotic efficacy with minimal impact on CRP or white blood cell counts, suggesting that DAT could be preferable for high-risk CCS patients. 🔗https://lnkd.in/eMv-Gjzr Follow us on 𝕏! https://lnkd.in/d7_4CjrN #platelets #plateletsjournal #DAPT #DAT #ticagrelor #rivaroxaban #CCS Dalhousie University

🦷 🛠️ Clinical Tool on FOR.org: Predict peri‑implantitis outcomes in 60 seconds Ever wondered how likely an implant with peri‑implant disease will stabilise after one year? Our evidence‑based Prognostic Tool—developed and validated by Prof. Miguel de Araújo Nobre et al.—delivers a personalised forecast using six quick clinical inputs (age, history of periodontitis, bone level, time in function, etc.). 👀 Watch the 45‑second walkthrough below to see a test case (48‑year‑old, mid‑third bone loss). Result? 59 % probability of favourable healing, 41 % risk of persistence risk_assessment_results 🦷 Why it matters • Sets realistic expectations for you and your patient • Supports shared decision‑making & tailored maintenance schedules • Free, browser‑based, and takes < 1 minute 👉 Try it now: https://lnkd.in/e3B8fEhZ

New on Foundation for Oral Rehabilitation (FOR) : a fast, evidence-based prognostic tool to assess peri-implantitis outcomes in under a minute. With just six clinical inputs, clinicians can estimate the likelihood of healing vs. persistence, supporting better patient communication and tailored care plans. 👉 Try it now: https://lnkd.in/e3B8fEhZ #Implantology #OralRehabilitation #ClinicalTools #NobelBiocare #FORorg

Individualized treatment recommendations based on artificial intelligence-supported evaluation of atherosclerotic plaque: At the 3rd QCI meeting in Berlin, organized by @teamDewey under the amazing guidance of Marc Dewey and @Tobias Schaeffter, we brought together a diverse group of experts to build consensus on atherosclerotic plaque evaluation and its implications for individualized treatment in patients with suspected coronary artery disease and stable chest pain. We discussed the current role of plaque phenotypes and highlighted the importance of non-calcified plaque in guiding clinical decision-making. 🧠 Key insights: 🔍 “Non-calcified plaque is most suited for monitoring of treatment and might be beneficial for the adjustment of treatment recommendations.” 🧪 Clinical trials comparing standard CT with AI-supported plaque evaluation are urgently needed to define its role in personalized decision-making. 💊 Lipid-lowering therapy should be initiated after any plaque detection — and intensified when total plaque volume exceeds the 70th percentile for age and gender. 🔗 Read the full consensus statement here: https://lnkd.in/gjVjPBV6 #CCTA #CardiovascularImaging #PlaqueGuidedCare #AIinMedicine #PrecisionMedicine #LipidLowering #Atherosclerosis #whycmr #yescct

For many patients, neuropathy presents a significant challenge to their quality of life and mobility. As healthcare professionals, we're constantly seeking effective, evidence-based solutions. Class 4 laser therapy is a proven, non-pharmacological treatment that addresses the root cause of nerve pain. By delivering targeted light energy, the therapy promotes mitochondrial activity and stimulates nerve regeneration, leading to improved circulation and reduced neuropathic symptoms. This technology represents a powerful advancement in non-invasive rehabilitation and pain management, offering a sustainable path to relief for those suffering from chronic nerve conditions. #HealthcareInnovation #MedicalTechnology #NeuropathyTreatment #PhysicalTherapy #Rehabilitation #PainManagement #SummusMedicalLaser

Demystifying Atypical-Site Thrombosis: When Clots Take the Road Less Travelled Exciting news! A new evidence-based guide focusing on atypical-site thrombosis is now accessible. In the realm of healthcare, encountering thrombosis in unexpected locations like cerebral, splanchnic, or renal veins can pose significant challenges due to their high morbidity and the absence of clear management protocols. My latest comprehensive guide delves into these intricate scenarios, offering actionable strategies to enhance patient outcomes. Here are the key highlights: - Embracing multidisciplinary approaches for rare yet high-risk thrombotic events - Exploring the latest evidence regarding DOAC use in unusual-site thrombosis - Implementing organ-specific management strategies rooted in recent research findings - Providing critical decision-making frameworks for anticoagulation in complex situations Whether you're navigating portal vein thrombosis, cerebral venous sinus thrombosis, or other atypical clots, this guide arms you with practical, evidence-based insights tailored for real-world clinical application. Stay at the forefront of thrombosis management to optimize patient outcomes! #VascularMedicine #Thrombosis #CerebralVenousThrombosis #SplanchnicVeinThrombosis #DOACs #Haematology #HematologyEducation #EvidenceBasedMedicine #ClinicalGuidelines #RareClots #PatientSafety #MedicalEducation #BloodDoctor #HematologyResearch

Individualized treatment recommendations through AI-supported quantification of total plaque volume percentiles: At the 3rd QCI meeting in Berlin, organized by Team Dewey under the amazing guidance of Marc Dewey and Tobias Schaeffter, we brought together a diverse group of experts to build consensus on atherosclerotic plaque evaluation and its implications for individualized treatment in patients with suspected coronary artery disease and stable chest pain. 🧠 Key insights: 🔍 “Non-calcified plaque is most suited for monitoring of treatment and might be beneficial for the adjustment of treatment recommendations.” 🧪 Clinical trials comparing standard CT with AI-supported plaque evaluation are urgently needed to define its role in personalized decision-making. 💊 Lipid-lowering therapy should be initiated after any plaque detection — and intensified when total plaque volume exceeds the 70th percentile for age and gender. 🔗 Read the full consensus statement here: https://lnkd.in/g68ZduzF Pál Maurovich-Horvat Marc Dewey #CCTA #CardiovascularImaging #PlaqueGuidedCare #AIinMedicine #PrecisionMedicine #LipidLowering #Atherosclerosis #whycmr #yescct